{"id":2163,"date":"2023-11-23T01:37:00","date_gmt":"2023-11-23T01:37:00","guid":{"rendered":"https:\/\/economicherald.net\/?p=2163"},"modified":"2023-11-23T01:37:00","modified_gmt":"2023-11-23T01:37:00","slug":"asx-health-stocks-chimeric-jumps-35pc-as-cell-therapy-drug-shows-pre-clinical-efficacy","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=2163","title":{"rendered":"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy"},"content":{"rendered":"<p>Chimeric\u2019s CHM 1301 demonstrates efficacy in pre-clinical trials<br \/>\nRecce granted Canadian patent<br \/>\nAlgorae announces\u00a0 collaboration with Monash University<\/p>\n<p>\u00a0<\/p>\n<h2>Chimeric shows pre-clinical efficacy<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/chimeric-therapeutics-chm\/\">Chimeric Therapeutics (ASX:CHM)<\/a><\/strong> continues to make progress in its multiple cell therapy programs.<\/p>\n<p>This morning, shares in the biotech rose 35% after announcing positive pre-clinical data for<strong> CHM 1301<\/strong>, its next generation, off-the-shelf <strong>CLTX CAR NK cell therapy.<\/strong><\/p>\n<p>Pre-clinical data showed that CHM 1301 demonstrated highly promising efficacy in in-vitro models.<\/p>\n<p>In ovarian cancer, results show that cell killing was increased up to ~260% as compared to first generation CHM 0201 cells, while in pancreatic cancer, cell killing was increased up to 300% as compared to first generation CHM 0201 cells.<\/p>\n<p>Based on this success, Chimeric said it will be advancing the CHM 1301 program to the next stage of pre-clinical development using its recently developed armoured NK cell platform <strong>(CHM 0301).<\/strong><\/p>\n<p>The positive results of CHM 1301 today also demonstrates the synergies of assets in the Chimeric portfolio.<\/p>\n<p>Today\u2019s results combine nicely with the recently announced efficacy of <strong>CHM 1101<\/strong>, Chimeric\u2019s CLTX CAR T cell therapy, and with the efficacy of <strong>CHM 02012<\/strong>, Chimeric\u2019s off-the-shelf NK cell platform \u2013 to create a whole new next generation of CLTX CAR NK cell therapy.<\/p>\n<p><strong>Jennifer Chow<\/strong>, CEO of Chimeric Therapeutics, said the results today also show the ability for Chimeric to expand into new disease areas.<\/p>\n<p>\u201cBeing able to achieve this success through our cost effective, academic collaboration with Dr David Wald at Case Western Reserve University also enables Chimeric to continue to build out a promising next generation pipeline, while focusing resources on our current clinical stage assets,\u201d she added.<\/p>\n<p>\u00a0<\/p>\n<h2>Recce granted Canadian patent<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/recce-pharmaceuticals-rce\/\">Recce Pharmaceuticals\u00a0(ASX:RCE)<\/a><\/strong> was granted Canadian patent claims related to <strong>RECCE 327 (R327<\/strong>) and <strong>RECCE 529 (R529)<\/strong> drugs<strong>.<\/strong><\/p>\n<p>Most notably, the patents relate to the process for preparation of RECCE anti-infectives, and the use of R327\/R529 for the treatment of disease, particularly in treatment of bacterial infections and viral infections.<\/p>\n<p>The patent also addresses and validates RECCE anti-infectives from studies in burn wounds, urinary tract infections, gonorrhoea, influenza, and SARS-CoV2.<\/p>\n<p>This is the first of Recce\u2019s wholly owned patents granted in Canada, with further Patent Cooperation Treaty Country (PCT) submissions already in respective stages of review.<\/p>\n<p>\u00a0<\/p>\n<h2>Cannabis biotech Algorae collaborates with Monash<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/algorae-pharmaceuticals-1ai\/\">Algorae Pharmaceuticals (ASX:1AI) <\/a><\/strong>announced a collaboration with <strong>Monash University<\/strong> to undertake pre-clinical studies on the <strong>AI-168<\/strong> drug candidate to treat cardiovascular diseases.<\/p>\n<p>AI-168 is made from cannabinoid and another pharmaceutical drug, with a patent application already filed.<\/p>\n<p>Under the agreement, Monash will employ a suite of state-of-the-art experimental techniques, which are expected to provide an understanding of the mechanism of action of AI-168 across a range of cardiovascular diseases (CVDs).<\/p>\n<p>The pre-clinical efficacy of AI-168 will then be compared to existing classes of drugs used to treat CVDs.<\/p>\n<p>Results are anticipated in multiple deliverable time frames over a period of approximately 12 months.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span><br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-chimeric-jumps-35pc-as-cell-therapy-drug-shows-pre-clinical-efficacy\/\">ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Chimeric\u2019s CHM 1301 demonstrates efficacy in pre-clinical trials Recce granted Canadian patent Algorae announces\u00a0 collaboration with Monash University \u00a0 Chimeric shows pre-clinical efficacy Chimeric Therapeutics <a href=\"https:\/\/economicherald.net\/?p=2163\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":2164,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-2163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=2163\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Chimeric\u2019s CHM 1301 demonstrates efficacy in pre-clinical trials Recce granted Canadian patent Algorae announces\u00a0 collaboration with Monash University \u00a0 Chimeric shows pre-clinical efficacy Chimeric Therapeutics [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=2163\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-23T01:37:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy\",\"datePublished\":\"2023-11-23T01:37:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163\"},\"wordCount\":508,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2163#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=2163\",\"name\":\"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg\",\"datePublished\":\"2023-11-23T01:37:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=2163\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=2163#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=2163","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy - Economic Herald","og_description":"Chimeric\u2019s CHM 1301 demonstrates efficacy in pre-clinical trials Recce granted Canadian patent Algorae announces\u00a0 collaboration with Monash University \u00a0 Chimeric shows pre-clinical efficacy Chimeric Therapeutics [more...]","og_url":"https:\/\/economicherald.net\/?p=2163","og_site_name":"Economic Herald","article_published_time":"2023-11-23T01:37:00+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=2163#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=2163"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy","datePublished":"2023-11-23T01:37:00+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=2163"},"wordCount":508,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=2163#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg","articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=2163#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=2163","url":"https:\/\/economicherald.net\/?p=2163","name":"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=2163#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=2163#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg","datePublished":"2023-11-23T01:37:00+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=2163#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=2163"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=2163#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/11\/Chimeric-jumps-35pc-as-CHM-1301-demonstrates-efficacy-in-pre-clinical-trials.-Picture-Getty-Uog4rU.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=2163#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2163"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/2163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/2164"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}